Skin News and Research

RSS

Study paves way for the creation of a stem cell library

The study, led by the University of Edinburgh's MRC Centre for Regenerative Medicine, paves the way for the creation of a stem cell library that can be used for in vitro hepatic disease models.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Update from SemBioSys Genetics regarding Botaneco Specialty Ingredients

SemBioSys Genetics Inc. today announced that Advitech Inc. ("Advitech") has entered into a definitive agreement to acquire all of the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and Avrio Ventures Limited Partnership ("Avrio").

21 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Researchers study reading and written comprehension skills of deaf youngsters

A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.

21 Oct 2009

Palmerolide A: Real hope for cancer treatment

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

21 Oct 2009

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn’s patents and IP in the emerging field of nanomedicine.

21 Oct 2009

Amputation prevention tips for diabetic patients

While "One Foot, Two Foot, Red Foot, Blue Foot" may be the opening line of a humorous children's book by Dr. Seuss, foot complications are no laughing matter to the 20 million Americans with diabetes. According to the American Orthopaedic Foot & Ankle Society (AOFAS), ulceration, infection, and gangrene are the most common foot and ankle problems of the diabetic patient.

21 Oct 2009

MediWound reports positive results from phase III Debrase trial for treating burns

Teva Pharmaceutical Industries Ltd. announced today that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase®, an enzymatic debriding agent for burns.

21 Oct 2009

Cork University Hospital uses a computer simulation system in its clinical trials

SensAble Technologies, Inc., announced that its customer, the Cork University Hospital, is leading clinical trials in two European hospitals using a haptically-enabled computer simulation system for testing physician competency in administering spinal anesthesia.

20 Oct 2009

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Mother Nature has provided the lizard with a unique ability to regrow body tissue that is damaged or torn ― if its tail is pulled off, it grows right back. She has not been quite so generous with human beings. But we might be able to come close, thanks to new research from Tel Aviv University.

20 Oct 2009

Scientists find cause for lupuslike disease in mice

Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.

19 Oct 2009

California's community hospitals launch public education and media campaign on H1N1

As preparations for the H1N1 flu season kick into high gear, California's community hospitals have launched a statewide public education and media campaign.

19 Oct 2009

Children with neurological disorders have low skin temperature

Many wheelchair-using children with neurological disorders have much colder hands and feet than other children, and most receive no special help even though they have had these problems for a long time, is revealed in at thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

19 Oct 2009

AccuVein signs five-year agreement with the Ferrer Group

AccuVein LLC today announced a five-year agreement with the Ferrer Group, a leading international pharmaceutical and medical devices distribution company, providing the AccuVein AV300, the world's first hand-held, non-contact vein illumination device, to customers in Greece, Spain and Portugal.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Premier Plastic Surgery of Kansas City, serving residents of Kansas City and beyond for 22 years, has redesigned its extensive website to include a separate section on Cosmetic Surgery for Males, a new Skin Care Centre, and a Plastic Surgery Blog that features breaking news on emerging research, techniques and products.

19 Oct 2009

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

19 Oct 2009